← All companies
About this company
RhyGaze AG, a spin-out from IOB, is developing a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness. Cones are the retinal cells responsible for high acuity vision and can lose their sensitivity to light in a range of diseases. RhyGaze's gene therapy solution delivers a new light-sensor gene specifically to cone cells that have lost light sensitivity, repairing their ability to detect light.